Roivant Sciences/$ROIV

Shares rise after Roivant and Priovant announced positive Phase 3 VALOR results for brepocitinib in dermatomyositis, with the 30 mg dose achieving significant improvement and NDA filing planned for 1H 2026.
15 hours agoLightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Roivant Sciences

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Ticker

$ROIV
Sector
Primary listing

Employees

750

Roivant Sciences Metrics

BasicAdvanced
$9.7B
-
-$0.69
1.15
-

What the Analysts think about Roivant Sciences

Analyst ratings (Buy, Hold, Sell) for Roivant Sciences stock.

Bulls say / Bears say

Roivant's loss from continuing operations widened to $252.4 million in the fourth quarter ended March 31, 2025, compared with $95.0 million a year earlier, challenging its path to profitability (BioSpace)
Research and development expenses surged by $37.7 million to $145.2 million for the quarter ended March 31, 2025, further increasing its cash burn (BioSpace)
Ongoing lipid nanoparticle (LNP) patent litigation against Moderna has entered the summary judgment phase, with a jury trial set for March 2026, presenting potential legal liabilities and distraction for management (GLOBE NEWSWIRE)
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2025.

Roivant Sciences Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Roivant Sciences Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ROIV

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs